Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 13, 2019 Filed Mar 15, 2019 20:42 UTC |
Mohindru ManiCFO & Chief Strategy Officer
|
SaleCommon Stock | 16,041 | $19.12 | $306,703.92 |
DisclosureSEC source: 0001209191-19-019712 · doc4.xml · nonDerivative · entry 2 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,026 F1 · kind: This exercise and corresponding sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:42 UTC |
Mohindru ManiCFO & Chief Strategy Officer
|
Exercise / conversionCommon Stock | 16,041 | $14.06 | $225,536.46 |
DisclosureSEC source: 0001209191-19-019712 · doc4.xml · nonDerivative · entry 1 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,067 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and corresponding sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 21:13 UTC |
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&D
|
SaleCommon Stock | 3,197 | $17.50 | $55,947.50 |
DisclosureSEC source: 0001209191-19-019509 · doc4.xml · nonDerivative · entry 1 Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,582 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.50 to $17.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 17:31 UTC |
CHALMERS DEREK TDirector · President & CEO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 235,000 | $0.00 Strike: $16.10 | $0.00 |
DisclosureSEC source: 0001209191-19-018214 · doc4.xml · derivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,000 Underlying: Common Stock · 235,000 shares Expires 2029-03-06 F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 6, 2019, in each case subject to the Reporting Person's Continuous service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 22:32 UTC |
Mohindru ManiCFO & Chief Strategy Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $16.10 | $0.00 |
DisclosureSEC source: 0001209191-19-018220 · doc4.xml · derivative · entry 1 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-03-06 F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 6, 2019, in each case subject to the Reporting Person's Continuous service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 22:33 UTC |
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&D
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $16.10 | $0.00 |
DisclosureSEC source: 0001209191-19-018222 · doc4.xml · derivative · entry 1 Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2029-03-06 F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 6, 2019, in each case subject to the Reporting Person's Continuous service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 22:32 UTC |
Terrillion ScottSec'y; Chief Compliance & G.C.
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $16.10 | $0.00 |
DisclosureSEC source: 0001209191-19-018218 · doc4.xml · derivative · entry 1 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-03-06 F1 · derivative.exercise_date: The shares shall vest in a series of 48 successive equal monthly installments beginning on April 6, 2019, in each case subject to the Reporting Person's Continuous service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 16:53 UTC |
CHALMERS DEREK TDirector · President & CEO
|
SaleCommon Stock | 9,792 | $17.04 | $166,855.68 |
DisclosureSEC source: 0001209191-19-016647 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 943,996 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.85 - $17.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 22:49 UTC |
Menzaghi Frederique Ph.D.Sr VP-Research & Development
|
SaleCommon Stock | 1,500 | $17.50 | $26,250.00 |
DisclosureSEC source: 0001209191-19-015839 · doc4.xml · nonDerivative · entry 1 Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,779 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2018. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 22:29 UTC |
Menzaghi Frederique Ph.D.Sr VP-Research & Development
|
SaleCommon Stock | 2,200 | $17.50 | $38,500.00 |
DisclosureSEC source: 0001209191-19-014161 · doc4.xml · nonDerivative · entry 1 Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,279 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.50 to $17.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 16:27 UTC |
CHALMERS DEREK TDirector · President & CEO
|
SaleCommon Stock | 20,000 | $14.99 | $299,800.00 |
DisclosureSEC source: 0001209191-19-007341 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 953,788 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.88 - $15.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| January 04, 2019 Filed Jan 4, 2019 16:22 UTC |
CHALMERS DEREK TDirector · President & CEO
|
SaleCommon Stock | 5,000 | $15.04 | $75,200.00 |
DisclosureSEC source: 0001209191-19-001924 · doc4.xml · nonDerivative · entry 2 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 973,788 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 - $15.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 16:22 UTC |
CHALMERS DEREK TDirector · President & CEO
|
SaleCommon Stock | 15,000 | $13.13 | $196,950.00 |
DisclosureSEC source: 0001209191-19-001924 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 978,788 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.83 - $13.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| December 28, 2018 Filed Jan 2, 2019 17:55 UTC |
CHALMERS DEREK TDirector · President & CEO
|
SaleCommon Stock | 15,825 | $12.53 | $198,287.25 |
DisclosureSEC source: 0001209191-19-000404 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 993,788 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of the restricted stock units reported in the Form 4 filed by the Reporting Person with the Securities and Exchange Commission on December 31, 2018, and does not represent a discretionary trade by the Reporting Person. F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding described above. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.49 - $12.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| December 28, 2018 Filed Jan 2, 2019 22:56 UTC |
Menzaghi Frederique Ph.D.Sr VP-Research & Development
|
SaleCommon Stock | 4,300 | $12.53 | $53,879.00 |
DisclosureSEC source: 0001209191-19-000406 · doc4.xml · nonDerivative · entry 1 Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,479 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting and of the restricted stock units reported in the Form 4 filed by the Reporting Person with the Securities and Exchange Commission on December 31, 2018, and does not represent a discretionary trade by the Reporting Person. F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding described above. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.50 to $12.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| December 28, 2018 Filed Jan 2, 2019 22:54 UTC |
Mohindru ManiCFO & Chief Strategy Officer
|
SaleCommon Stock | 4,500 | $12.55 | $56,475.00 |
DisclosureSEC source: 0001209191-19-000403 · doc4.xml · nonDerivative · entry 1 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,026 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting and of the restricted stock units reported in the Form 4 filed by the Reporting Person with the Securities and Exchange Commission on December 31, 2018, and does not represent a discretionary trade by the Reporting Person. F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding described above. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.53 - $12.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| December 28, 2018 Filed Jan 2, 2019 22:56 UTC |
Terrillion ScottSec'y; Chief Compliance & G.C.
|
SaleCommon Stock | 3,100 | $12.51 | $38,781.00 |
DisclosureSEC source: 0001209191-19-000405 · doc4.xml · nonDerivative · entry 1 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,386 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting and of the restricted stock units reported in the Form 4 filed by the Reporting Person with the Securities and Exchange Commission on December 31, 2018, and does not represent a discretionary trade by the Reporting Person. F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding described above. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.48 - $12.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| December 27, 2018 Filed Dec 31, 2018 16:15 UTC |
CHALMERS DEREK TDirector · President & CEO
|
GrantCommon Stock | 38,221 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-064402 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,009,613 F1 · shares: Represents the vesting in full of a performance-based restricted stock unit award based on the Issuer's satisfaction of certain performance criteria. In light of the performance-based vesting conditions of the award, such award was not reportable under Section 16 until vesting was determined, which occurred on December 27, 2018. Each restricted stock unit represented the contingent right to receive one share of common stock of the Issuer. Read SEC document |
| December 27, 2018 Filed Dec 31, 2018 21:19 UTC |
Terrillion ScottSec'y; Chief Compliance & G.C.
|
GrantCommon Stock | 9,486 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-064405 · doc4.xml · nonDerivative · entry 1 Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,486 F1 · shares: Represents the vesting in full of a performance-based restricted stock unit award based on the Issuer's satisfaction of certain performance criteria. In light of the performance-based vesting conditions of the award, such award was not reportable under Section 16 until vesting was determined, which occurred on December 27, 2018. Each restricted stock unit represented the contingent right to receive one share of common stock of the Issuer. Read SEC document |
| December 27, 2018 Filed Dec 31, 2018 21:18 UTC |
Menzaghi Frederique Ph.D.Sr VP-Research & Development
|
GrantCommon Stock | 11,779 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-064404 · doc4.xml · nonDerivative · entry 1 Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,779 F1 · shares: Represents the vesting in full of a performance-based restricted stock unit award based on the Issuer's satisfaction of certain performance criteria. In light of the performance-based vesting conditions of the award, such award was not reportable under Section 16 until vesting was determined, which occurred on December 27, 2018. Each restricted stock unit represented the contingent right to receive one share of common stock of the Issuer. Read SEC document |
| December 27, 2018 Filed Dec 31, 2018 21:17 UTC |
Mohindru ManiCFO & Chief Strategy Officer
|
GrantCommon Stock | 12,526 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-064403 · doc4.xml · nonDerivative · entry 1 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,526 F1 · shares: Represents the vesting in full of a performance-based restricted stock unit award based on the Issuer's satisfaction of certain performance criteria. In light of the performance-based vesting conditions of the award, such award was not reportable under Section 16 until vesting was determined, which occurred on December 27, 2018. Each restricted stock unit represented the contingent right to receive one share of common stock of the Issuer. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 16:16 UTC |
CHALMERS DEREK TDirector · President & CEO
|
SaleCommon Stock | 20,000 | $18.17 | $363,400.00 |
DisclosureSEC source: 0001209191-18-061248 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 971,392 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.01 - $18.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 21:18 UTC |
Menzaghi Frederique Ph.D.Sr VP-Research & Development
|
SaleCommon Stock | 3,000 | $18.36 | $55,080.00 |
DisclosureSEC source: 0001209191-18-061253 · doc4.xml · nonDerivative · entry 1 Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.3001 to $18.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 21:22 UTC |
Mohindru ManiCFO & Chief Strategy Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 16,042 | $0.00 Strike: $14.06 | $0.00 |
DisclosureSEC source: 0001209191-18-058944 · doc4.xml · derivative · entry 3 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,916 Underlying: Common Stock · 16,042 shares Expires 2027-08-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and corresponding sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018. F2 · derivative.exercise_date: One-fourth (1/4th) of the 385,000 shares subject to this option vested and became exercisable on August 15, 2018; the balance of the shares shall vest and become exercisable in a series of 36 successive equal monthly installments measured from August 15, 2018, subject to the reporting person's continuous service with the issuer as of each such date. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 21:22 UTC |
Mohindru ManiCFO & Chief Strategy Officer
|
SaleCommon Stock | 16,042 | $18.50 | $296,777.00 |
DisclosureSEC source: 0001209191-18-058944 · doc4.xml · nonDerivative · entry 2 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This exercise and corresponding sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 21:22 UTC |
Mohindru ManiCFO & Chief Strategy Officer
|
Exercise / conversionCommon Stock | 16,042 | $14.06 | $225,550.52 |
DisclosureSEC source: 0001209191-18-058944 · doc4.xml · nonDerivative · entry 1 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and corresponding sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 17:35 UTC |
CHALMERS DEREK TDirector · President & CEO
|
SaleCommon Stock | 20,000 | $18.78 | $375,600.00 |
DisclosureSEC source: 0001209191-18-056972 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 991,392 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.53 - $18.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| November 01, 2018 Filed Nov 6, 2018 01:25 UTC |
Menzaghi Frederique Ph.D.Sr VP-Research & Development
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001209191-18-057307 · doc4.xml · derivative · entry 3 Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2020-10-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| November 01, 2018 Filed Nov 6, 2018 01:25 UTC |
Menzaghi Frederique Ph.D.Sr VP-Research & Development
|
SaleCommon Stock | 3,000 | $18.77 | $56,310.00 |
DisclosureSEC source: 0001209191-18-057307 · doc4.xml · nonDerivative · entry 2 Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.62 to $18.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| November 01, 2018 Filed Nov 6, 2018 01:25 UTC |
Menzaghi Frederique Ph.D.Sr VP-Research & Development
|
Exercise / conversionCommon Stock | 40,000 | $2.05 | $82,000.00 |
DisclosureSEC source: 0001209191-18-057307 · doc4.xml · nonDerivative · entry 1 Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 20:32 UTC |
Goncalves JoanaChief Medical Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $19.27 | $0.00 |
DisclosureSEC source: 0001209191-18-056060 · doc4.xml · derivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2028-10-22 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares shall vest and become exercisable on October 22, 2019; the balance of the shares shall vest and become exercisable in a series of 36 successive equal monthly installments measured from October 22, 2019, subject to the reporting person's continuous service with the issuer as of each such date. Read SEC document |
| October 17, 2018 Filed Oct 19, 2018 16:34 UTC |
Stauffer Joseph WilliamChief Medical Officer
|
SaleCommon Stock | 970 | $20.69 | $20,069.30 |
DisclosureSEC source: 0001209191-18-055688 · doc4.xml · nonDerivative · entry 2 Stauffer Joseph William · CIK 0001466459 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.60 - $20.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| October 17, 2018 Filed Oct 19, 2018 16:34 UTC |
Stauffer Joseph WilliamChief Medical Officer
|
SaleCommon Stock | 10,472 | $20.08 | $210,277.76 |
DisclosureSEC source: 0001209191-18-055688 · doc4.xml · nonDerivative · entry 1 Stauffer Joseph William · CIK 0001466459 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,970 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.60 - $20.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| October 17, 2018 Filed Oct 19, 2018 20:32 UTC |
Mohindru ManiCFO & Chief Strategy Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 16,042 | $0.00 Strike: $14.06 | $0.00 |
DisclosureSEC source: 0001209191-18-055685 · doc4.xml · derivative · entry 3 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,958 Underlying: Common Stock · 16,042 shares Expires 2027-08-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to this option vested and became exercisable on August 15, 2018; the balance of the shares shall vest and become exercisable in a series of 36 successive equal monthly installments measured from August 15, 2018, subject to the reporting person's continuous service with the issuer as of each such date. Read SEC document |
| October 17, 2018 Filed Oct 19, 2018 20:32 UTC |
Mohindru ManiCFO & Chief Strategy Officer
|
SaleCommon Stock | 16,042 | $20.19 | $323,887.98 |
DisclosureSEC source: 0001209191-18-055685 · doc4.xml · nonDerivative · entry 2 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.72 - $20.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| October 17, 2018 Filed Oct 19, 2018 20:32 UTC |
Mohindru ManiCFO & Chief Strategy Officer
|
Exercise / conversionCommon Stock | 16,042 | $14.06 | $225,550.52 |
DisclosureSEC source: 0001209191-18-055685 · doc4.xml · nonDerivative · entry 1 Mohindru Mani · CIK 0001664708 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 16:08 UTC |
CHALMERS DEREK TDirector · President & CEO
|
SaleCommon Stock | 20,000 | $23.79 | $475,800.00 |
DisclosureSEC source: 0001209191-18-053762 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,011,392 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.3501 - $24.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 20:09 UTC |
Menzaghi Frederique Ph.D.Sr VP-Research & Development
|
SaleCommon Stock | 3,000 | $23.99 | $71,970.00 |
DisclosureSEC source: 0001209191-18-053764 · doc4.xml · nonDerivative · entry 1 Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.90 to $24.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 17:34 UTC |
CHALMERS DEREK TDirector · President & CEO
|
SaleCommon Stock | 20,000 | $19.71 | $394,200.00 |
DisclosureSEC source: 0001209191-18-049923 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,031,392 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.30 - $20.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 21:33 UTC |
Menzaghi Frederique Ph.D.Sr VP-Research & Development
|
SaleCommon Stock | 3,000 | $19.81 | $59,430.00 |
DisclosureSEC source: 0001209191-18-049921 · doc4.xml · nonDerivative · entry 1 Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.581 to $20.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 21:26 UTC |
Menzaghi Frederique Ph.D.Sr VP-Research & Development
|
SaleCommon Stock | 3,000 | $18.89 | $56,670.00 |
DisclosureSEC source: 0001209191-18-048017 · doc4.xml · nonDerivative · entry 1 Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.80 to $18.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| August 06, 2018 Filed Nov 6, 2018 01:21 UTC |
Menzaghi Frederique Ph.D.Sr VP-Research & Development
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001209191-18-057306 · doc4.xml · derivative · entry 2 Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2018-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| August 06, 2018 Filed Nov 6, 2018 01:21 UTC |
Menzaghi Frederique Ph.D.Sr VP-Research & Development
|
Exercise / conversionCommon Stock | 10,000 | $2.25 | $22,500.00 |
DisclosureSEC source: 0001209191-18-057306 · doc4.xml · nonDerivative · entry 1 Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 21:54 UTC |
Posner ChristopherDirector
|
GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $17.94 | $0.00 |
DisclosureSEC source: 0001209191-18-045588 · doc4.xml · derivative · entry 1 Posner Christopher · CIK 0001748265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2028-08-02 F1 · derivative.exercise_date: This option was granted to the reporting person pursuant to the issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable in three equal annual installments beginning on August 2, 2019, subject to the reporting person's continued service as a director through each such vesting date. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 16:42 UTC |
CHALMERS DEREK TDirector · President & CEO
|
SaleCommon Stock | 20,000 | $20.64 | $412,800.00 |
DisclosureSEC source: 0001209191-18-042466 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,051,392 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.06 - $20.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 21:00 UTC |
Menzaghi Frederique Ph.D.Sr VP-Research & Development
|
SaleCommon Stock | 3,000 | $19.00 | $57,000.00 |
DisclosureSEC source: 0001209191-18-041722 · doc4.xml · nonDerivative · entry 1 Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2017. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 16:31 UTC |
VOGELBAUM MARTINDirector
|
GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $16.07 | $0.00 |
DisclosureSEC source: 0001209191-18-036696 · doc4.xml · derivative · entry 1 VOGELBAUM MARTIN · CIK 0001237624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2028-06-06 F1 · derivative.exercise_date: This option was granted to the reporting person pursuant to the issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on June 6, 2019, subject to the reporting person's continued service as a director through such date. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 16:30 UTC |
BAINS HARRISON M JRDirector
|
GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $16.07 | $0.00 |
DisclosureSEC source: 0001209191-18-036694 · doc4.xml · derivative · entry 1 BAINS HARRISON M JR · CIK 0001202282 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2028-06-06 F1 · derivative.exercise_date: This option was granted to the reporting person pursuant to the issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on June 6, 2019, subject to the reporting person's continued service as a director through such date. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 20:32 UTC |
Ives Jeffrey L.Director
|
GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $16.07 | $0.00 |
DisclosureSEC source: 0001209191-18-036698 · doc4.xml · derivative · entry 1 Ives Jeffrey L. · CIK 0001614096 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2028-06-06 F1 · derivative.exercise_date: This option was granted to the reporting person pursuant to the issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on June 6, 2019, subject to the reporting person's continued service as a director through such date. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 23:15 UTC |
Menzaghi Frederique Ph.D.Sr VP-Research & Development
|
SaleCommon Stock | 3,000 | $15.49 | $46,470.00 |
DisclosureSEC source: 0001209191-18-035933 · doc4.xml · nonDerivative · entry 1 Menzaghi Frederique Ph.D. · CIK 0001597152 · Sr VP-Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.4501 to $15.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.